Early phase clinical studies of AR ‐42, a histone deacetylase inhibitor, for neurofibromatosis type 2‐associated vestibular schwannomas and meningiomas-Reference-Cited by-同舟云学术

Early phase clinical studies of AR ‐42, a histone deacetylase inhibitor, for neurofibromatosis type 2‐associated vestibular schwannomas and meningiomas

Published:2021-08-20 Issue:5 Volume:6 Page:1008-1019
ISSN:2378-8038
Container-title:Laryngoscope Investigative Otolaryngology
language:en
Short-container-title:Laryngoscope Investigative Otolaryngology

Author:

Welling D. Bradley¹^ORCID,Collier Katharine A.²^ORCID,Burns Sarah S.³⁴,Oblinger Janet L.³⁴,Shu Edina¹,Miles‐Markley Beth A.⁵,Hofmeister Craig C.⁶,Makary Mina S.⁷,Slone H. Wayne⁷,Blakeley Jaishri O.⁸,Mansouri S. Alireza⁸,Neff Brian A.⁹,Jackler Robert K.¹⁰^ORCID,Mortazavi Amir²,Chang Long‐Sheng³⁴⁵

Affiliation:

1. Department of Otolaryngology Head and Neck Surgery Harvard Medical School, Massachusetts Eye and Ear Infirmary, Massachusetts General Hospital Boston Massachusetts USA

2. Division of Medical Oncology, Department of Internal Medicine The Ohio State University College of Medicine and the Comprehensive Cancer Center Columbus Ohio USA

3. Center for Childhood Cancer and Blood diseases Abigail Wexner Research Institute at Nationwide Children's Hospital Columbus Ohio USA

4. Department of Pediatrics The Ohio State University College of Medicine Columbus Ohio USA

5. Department of Otolaryngology‐Head and Neck Surgery The Ohio State University College of Medicine Columbus Ohio USA

6. Department of Hematology & Oncology Winship Cancer Institute of Emory University Atlanta Georgia USA

7. Department of Radiology The Ohio State University College of Medicine Columbus Ohio USA

8. Departments of Neurology, Neurosurgery, & Oncology Johns Hopkins University Baltimore Maryland USA

9. Department of Otolaryngology Head and Neck Surgery Mayo Clinic Rochester Minnesota USA

10. Department of Otolaryngology Head and Neck Surgery Stanford University Palo Alto California USA

Funder

National Cancer Institute

U.S. Department of Defense

Publisher

Wiley

Subject

General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/lio2.643

Reference55 articles.

1. A phase 1 trial of the histone deacetylase inhibitor AR-42 in patients with neurofibromatosis type 2-associated tumors and advanced solid malignancies

2. Neurofibromatosis type 2

3. A clinical study of type 2 neurofibromatosis;Evans DG;Q J Med,1992

4. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2013–2017

5. Cancer and Central Nervous System Tumor Surveillance in Pediatric Neurofibromatosis 1

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Fermented Wheat Germ Protein with Histone Deacetylase Inhibitor AR42 Demonstrates Enhanced Cytotoxicity against Lymphoma Cells In Vitro and In Vivo;International Journal of Molecular Sciences;2024-07-18

2. Targeting histone deacetylase 6 (HDAC6) to enhance radiation therapy in meningiomas in a 2D and 3D in vitro study;eBioMedicine;2024-07

3. NF2-Related Schwannomatosis (NF2): Molecular Insights and Therapeutic Avenues;International Journal of Molecular Sciences;2024-06-14

4. Noncoding RNA landscape and their emerging roles as biomarkers and therapeutic targets in meningioma;Molecular Therapy: Oncology;2024-03

5. From bench to bedside: Advancing towards therapeutic treatment of vestibular schwannomas;Neuro-Oncology Advances;2024-01-01